Mechanism of Action (MOA) Studies for Bladder Cancer
Mechanism of Action (MOA) studies are essential in unraveling the intricate molecular processes involved in bladder cancer. At Alfa Cytology, we have established a comprehensive platform dedicated to studying the mechanisms of action for bladder cancer. Our goal is to enhance our understanding of the disease and contribute to the development of effective therapeutic strategies.
MOA Studies for Bladder Cancer
Bladder cancer is a complex and challenging disease characterized by the uncontrolled growth and spread of malignant cells in the urinary bladder. Understanding the underlying mechanisms of bladder cancer development and progression is crucial for the development of effective therapeutic interventions. MOA studies play a vital role in unraveling the intricate molecular processes involved in bladder cancer.
Fig.1 The mechanism of action of BCG therapy for bladder cancer. (Redelman-Sidi G., et al. 2014)
Areas of focus for research on mechanisms of action in bladder cancer include:
Signaling Pathways and Epithelial-Mesenchymal Transition (EMT)
Signaling pathways such as TGF-β, Wnt/β-catenin and Notch are involved in the development of EMT, an important process leading to the loss of intercellular adhesion and the acquisition of a mesenchymal phenotype by epithelial cells. This phenotypic shift allows bladder cancer cells to migrate, invade surrounding tissues and promote metastasis.
Fig 2. Signaling Pathways and Epithelial-Mesenchymal Transition (EMT). (Dongre A., et al. 2019)
Angiogenesis and Tumor Growth
Overexpression of vascular endothelial growth factor (VEGF) and angiogenesis-promoting factors has been shown to promote angiogenesis, support bladder tumor growth, and facilitate cancer cell metastasis to distant organs.
Fig 3. Angiogenesis and Tumor Growth. (Dudley A. C., et al. 2023)
Extracellular Matrix (ECM) Remodeling and Invasion
Bladder cancer cells secrete enzymes such as matrix metalloproteinases (MMP), including MMP-2 and MMP-9, which break down the ECM. This degradation allows the cancer cells to invade surrounding tissue and spread through the bloodstream and lymphatic pathways, contributing to the formation of metastatic lesions.
Fig 4. Extracellular Matrix (ECM) Remodeling and Invasion. (Winkler J., et al. 2020)
Immune Evasion and Metastasis
Bladder cancer cells use a variety of strategies to evade immune surveillance and promote metastasis. For example, they downregulate major histocompatibility complex (MHC) molecules and secrete immunosuppressive factors to inhibit the immune response and promote survival and metastasis of metastatic bladder cancer cells.
Fig 5. Immune Evasion and Metastasis. (Crispen P. L., et al. 2020)
Our Services
At Alfa Cytology, we are committed to advancing our understanding of bladder cancer through cutting-edge mechanism of action (MOA) studies. Our team of highly skilled and experienced researchers utilizes state-of-the-art techniques and technologies to investigate the intricate molecular processes underlying bladder cancer. We provide one-stop MOA study services including but not limited to:
- Drug Resistance Mechanism Study Service for Bladder Cancer
Our approach involves investigating the molecular pathways and cellular processes that contribute to drug resistance in bladder cancer. By analyzing specific genetic alterations, signaling pathways, and cellular mechanisms, we can identify potential targets for therapeutic intervention.
- Mechanism Study Service for Metastatic Bladder Cancer
Our studies focus on unraveling the molecular processes involved in tumor cell invasion, migration, and establishment of secondary tumors. By investigating key signaling pathways, extracellular matrix remodeling, angiogenesis, and immune evasion mechanisms, we aim to identify novel targets for therapeutic intervention.
Contact Us
Alfa Cytology is committed to advancing the understanding of bladder cancer through our comprehensive MOA studies. Our team of experienced biological specialists possesses the expertise and state-of-the-art technologies necessary to conduct in-depth investigations into the mechanisms driving bladder cancer development, drug resistance, and metastasis. For more information about our services and collaborations, please contact us today.
References
- Redelman-Sidi G., Glickman M. and Bochner B. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol. 2014, 11, 153-162.
- Winkler J., Abisoye-Ogunniyan A., and et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020, 11, 5120.
- Dongre A., Weinberg R. A. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019, 20, 69–84.
- Crispen P. L., Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020, 69, 3–14.
- Dudley A. C., Griffioen A. W. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023, 26, 313–347.
For research use only. Not intended for any clinical use.
Related Services
